News articles about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9255081835457 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Trending Hot Stock’s Analysis: Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) – Alpha Beta Stock (alphabetastock.com)
- Top RSI Trades for Today: Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) – The Investor Guide (wallstreetnews24.com)
- Cyclacel Pharmaceuticals, Inc. (CYCC) stock dipped -42.33% Quarterly performance – Street Observer (press release) (streetobserver.com)
- Signals from Technical Perspective: Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) – Alpha Beta Stock (alphabetastock.com)
- Volatile Stock to Watch: Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) – Alpha Beta Stock (alphabetastock.com)
Shares of Cyclacel Pharmaceuticals (NASDAQ CYCC) opened at 2.00 on Monday. Cyclacel Pharmaceuticals has a one year low of $1.56 and a one year high of $10.90. The firm’s 50-day moving average price is $1.78 and its 200-day moving average price is $3.47.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter. On average, equities research analysts expect that Cyclacel Pharmaceuticals will post ($2.25) EPS for the current year.
In other news, major shareholder Eastern Capital Ltd acquired 850,000 shares of the firm’s stock in a transaction on Wednesday, July 19th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $1,700,000.00. Following the completion of the transaction, the insider now owns 2,167,261 shares of the company’s stock, valued at $4,334,522. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.00% of the stock is currently owned by insiders.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.